Trial Profile
Efficacy and Safety Study of Acoziborole (SCYX-7158) in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Gambiense: a Multicentre, Open-label, Prospective Study
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 21 Jan 2022
Price :
$35
*
At a glance
- Drugs Acoziborole (Primary)
- Indications African trypanosomiasis
- Focus Therapeutic Use
- Acronyms OXA002
- 17 Jan 2022 Status changed from active, no longer recruiting to completed.
- 21 Feb 2020 Planned End Date changed from 1 Jun 2020 to 1 Sep 2020.
- 21 Feb 2020 Planned primary completion date changed from 1 Apr 2020 to 1 Sep 2020.